This week, we have a conversation with congenital myotonic dystrophy patient advocacy consultant Lisa Harvey-Duren, who was the founding Myotonic Dystrophy Foundation executive director in 2008, and Michael Snape, CEO and CSO of AMO Pharma, which is developing a treatment for the disease.
AMO Pharma
AMO Pharma is a clinical-stage specialty biopharmaceutical company working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare and severe childhood onset neurogenetic disorders with limited or no treatment options.
In addition to developing AMO-02 for congenital myotonic dystrophy, the company is also progressing AMO-02 as a clinical stage treatment for arrhythmogenic right ventricular cardiomyopathy.
AMO-01 is being investigated for treatment of Phelan-McDermid syndrome and AMO-04 as a clinic-ready potential medicine for Rett syndrome and related disorders.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com